+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07522099

Evaluation of ADX-038 Alone and Combined with Telitacicept for Chinese Adults With Complement-Mediated Kidney Diseases

Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-09-03

30

Participants Needed

9

Research Sites

27 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, pharmacokinetics, and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. This Phase 2 study includes Chinese adults diagnosed with IgA nephropathy, complement 3 glomerulopathy C3G, and immune complex membranoproliferative glomerulonephritis IC-MPGN. The study aims to better understand how ADX-038 works alone and in combination with telitacicept to treat these kidney conditions. The study has two parts Part A tests ADX-038 alone, while Part B tests ADX-038 combined with telitacicept. Both treatments are given to participants who meet the criteria. The study is non-randomized and parallel in design, allowing comparison of the two treatment approaches. Part A lasts 24 months, and Part B lasts 15 months, during which participants receive the study drugs. Participants will be monitored throughout the study for safety and tolerability of the treatments. Researchers will collect data on kidney function and other health measures to evaluate treatment impact. The study includes assessments such as kidney biopsies and vaccinations as required. Total participation may last up to two years depending on the treatment part assigned.

CONDITIONS

Brief Title

Chinese Adults With Kidney Disease

Research Team

S

Stephanie Leyva

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here